Volume 208 - Issue 4
Hepatitis C in Australia — a role for general practitioners?
Authors: David Baker, Marilyn McMurchie and Vanessa Farr
Med J Aust 2018; 208 (4): 190. || doi: 10.5694/mja17.00733
Published online: 5 March 2018
Published online: 5 March 2018
To the Editor:
After reading the recent article by van Driel and colleagues,1 we want to report on hepatitis C treatment outcomes in a Sydney general practice.
New direct-acting antiviral (DAA) therapy for the treatment of chronic hepatitis C became widely available in Australia on 1 March 2016 via the Pharmaceutical Benefits Scheme, and general practitioners are able to prescribe it in consultation with a specialist. We describe here the treatment outcomes from the first 60 days of DAA prescribing in a single general practice clinic.
We searched the clinic database to extract demographic and clinical data for all patients prescribed DAA from 1 March to 30 April 2016. We found that 47 patients had been prescribed DAA agents by a GP, five had received DAA therapy via an early access program, 41 had genotype 1 hepatitis C virus (HCV), six patients had genotype 3 HCV, and 11 patients had co-infection with HIV. All treated patients had an assessment of liver fibrosis performed with a FibroScan. Most patients had early liver disease, with three having cirrhosis. On 1 May 2017, we assessed the outcome data: 33 patients were treated with ledipasvir and sofosbuvir (all had genotype 1 HCV), nine were treated with daclatasvir and sofosbuvir (three had genotype 1 HCV, and six had genotype 3 HCV), and five patients were treated with paritaprevir + ritonavir + ombitasvir + dasabuvir (all had genotype 1 HCV). Forty-six patients had started treatment, with sustained virological response (SVR16; ie, undetectable virus 16 weeks after the end of treatment) results available for 45 patients. One patient had treatment failure, one had not started treatment and one patient was waiting on SVR results. On-treatment SVR (cure) rate was 96%.
A steadily increasing percentage of patients in Australia are receiving hepatitis C treatment prescribed by their GPs, with 19% of prescriptions provided in this setting in September 2016.2 GPs are well placed to provide care for patients living with chronic hepatitis C, with reassuringly high cure rates.
Competing interests
D Baker has received funding for conferences, research and advisory board membership from Gilead, Bristol-Myers Squibb, AbbVie and Merck.
References
- van Driel ML, Lim D, Clark PJ. Hepatitis C in Australia — a role for general practitioners? Med J Aust 2017; 207: 53.
- Kirby Institute. Monitoring hepatitis C treatment uptake in Australia: issue 6. Sydney: Kirby Institute, University of New South Wales; 2017. https://kirby.unsw.edu.au/sites/default/files/kirby/report/Monitoring-hep-C-treatment-uptake-in-Australia_Iss6-FEB17.pdf (viewed Dec 2017).
Early-Onset Colorectal Cancer With Liver-Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real-World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning
Savio G. Barreto, Christos S. Karapetis, Shahid Ullah, Matthew Burge, Susan Caird, Angus Campbell, Azim Jalali, Ross Jennens, Muhammad A. Khattak, Belinda Lee, Stephanie H. Lim, Shehara Mendis, Louise Nott, Timothy J. Price, Jeremy D. Shapiro, Jeanne Tie, Javier Torres, Colin Williams, Rachel Wong, Vanessa Wong, Peter Gibbs
Australian Pathways for Specialist Pain Management and Early Palliative Care for People With Pancreatic Cancer: Developed Using a Community Consensus Approach
Jennifer Philip, Melanie R. Lovell, Kylee Bellingham, Gail Garvey, Gregory B. Crawford, Nicole M. Rankin, Kara Burns, Isabel Young, Vivienne Milch, Dorothy Keefe, Katrina Anderson, James Lawson, Meinir Krishnasamy
Cause‐specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007–22: a retrospective cohort study
Vikas Bhasker, Jessica R Fong, Paul J Clark, Gunter F Hartel, Richard Skoien, James O’Beirne, Elizabeth E Powell, Patricia C Valery
Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations
Jacob George, Nicole L Allard, Stuart K Roberts, Leon A Adams, Jane Davies, Behzad Hajarizadeh, Jennifer H MacLachlan, Suzanne E Mahady, Rosalie Altus, Catherine Brown, David C Fry, Belinda Greenwood‐Smith, Natali Smud, Patricia C Valery, Nafisa Yussf, Kate Broun, Denise Campbell, Karen Canfell, Chelsea Carle Harrison, Victoria Freeman, Paul Grogan, Catherine Holliday, Suzanne Hughes, Anna Kelly, Cathelijne Kemenade, Claire Latumahina, Amanda McAtamney, Megan Varlow, Joachim Worthington, Susan Yuill, Eleonora Feletto
Assessment of metabolic dysfunction‐associated fatty liver disease in primary care: a consensus statement summary
Leon A Adams, William W Kemp, Kate R Muller, Elizabeth E Powell, Stuart K Roberts, Luis Calzadilla Bertot, Stephanie Best, Gary Deed, Jon D Emery, Samantha L Hocking, Graham R Jones, John S Lubel, Sinead Sheils, Stephen M Twigg, Gerald F Watts, Jacob George
Treatment outcomes for people with hepatitis C referred to tertiary care in Victoria, 2021–22: a retrospective observational study
Elly Layton, Nicole Matthews, Brendan Quinn, Nasra Higgins, Gabrielle Lindeman, Mielle Abbott, Jennifer MacLachlan, Elizabeth Birbilis, Margaret E Hellard, Joseph Doyle, Benjamin C Cowie, Mark Stoové